United Therapeutics (UTHR) Tops Q2 EPS Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
United Therapeutics (UTHR) PT, Estimate Raised at BMO Capital
July 29, 2014 3:44 PM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on United Therapeutics Corp. (NASDAQ: UTHR) to $165.00 (from $150.00) following strong Q2 results.
"We maintain our Outperform rating on shares of UTHR following review of 2Q14 results. With above-consensus... More
